Prader-Willi Syndrome Clinical Trial
Official title:
Therapeutic Effects of Hippotherapy in Children With Prader-Willi Syndrome
This study evaluates the therapeutic effects of hippotherapy in children with Prader-Willi syndrome. Half of children will participate in hippotherapy for 15 weeks (30 minutes per sessions, twice a week, total 30 sessions, private lesson), while the other half will not receive hippotherapy.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2019 |
Est. primary completion date | June 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 42 Months to 12 Years |
Eligibility |
Inclusion Criteria: - can sit upright on the static surface - can follow one step command Exclusion Criteria: - body wight > 35 kg - serious medical conditions such as cardiac disease, pulmonary disease, uncontrolled epilepsy - visual impairment, hearing impairment - bleeding tendency, anticoagulation - fracture within 6 months, major orthopedic surgery within 1 year |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center | Samsung Electronics |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical global Impression-Severity of illness (CGI-S) score | The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. The two components of CGI were used in this study: Severity of Illness (CGI-S) and Global improvement (CGI-I). The clinician rates CGI-S on a 7-point scale from 1(normal) to 7(extremely ill) Thus, higher score means more severity outcomes | 15 weeks | |
Primary | Clinical global Impression-Improvement (CGI-I) score | The clinician rates CGI-I on a 7-point scale from 1(very much improved) to 7(very much worse) respectively. Thus, higher score means worse outcomes. | 15 weeks | |
Secondary | Gross motor function assessed by GMFM-88 (Gross Motor Function Measure) score | The 88 items of the GMFM are measured by observation of the child and scored on a 4-point ordinal scale (0=does not initiate, 1=initiates <10% of activity, 2=partially completes 10% to <100% of activity, 3=completes activity). The items are weighted equally and grouped into 5 dimensions: (1) lying and rolling (17 items), (2) sitting (20 items), (3) crawling and kneeling (14 items), (4) standing (13 items), and (5) walking, running, jumping (24 items). | 15 weeks | |
Secondary | Pediatric Balance Scale | The Pediatric Balance Scale is a modified version of the Berg Balance Scale that is used to assess functional balance skills in school-aged children. The scale consists of 14 items that are scored from 0 points (lowest function) to 4 points (highest function) with a maximum score of 56 points. | 15 weeks | |
Secondary | PWS (Prader-Willi syndrome) hyperphagia questionnaire | The Hyperphagia Questionnaire is a robust tool for relating breakthroughs in the neurobiology of hyperphagia to in vivo food-seeking behavior and for examining the psychological and developmental correlates of hyperphagia in PWS. It has 13 items and rated on a five-point scale (1 = not a problem to 5 = severe and/or frequent problem) | 15 weeks | |
Secondary | Child Behavior Checklist (CBCL) | The Child Behavior Checklist (CBCL) is a widely used caregiver report form identifying problem behavior in children. CBCL asks caregivers to rate 112 problems on a three-point scale (0 not true, 1 somewhat true, 2 very true). It provides an internalizing and externalizing domain. | 15 weeks | |
Secondary | Obesity measured by DEXA (Dual-energy X-ray Absorptiometry) | Dual-energy X-ray Absorptiometry is a means of measuring bone mineral density (BMD). Two X-ray beams, with different energy levels, are aimed at the patient's bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone. Dual-energy X-ray absorptiometry is the most widely used and most thoroughly studied bone density measurement technology. | 15 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05032326 -
Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial
|
Phase 3 | |
Completed |
NCT04526379 -
Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation
|
N/A | |
Terminated |
NCT03458416 -
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
|
Phase 2 | |
Completed |
NCT03718416 -
Natural History Study of Serious Medical Events in PWS
|
||
Completed |
NCT05322096 -
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
|
Phase 2 | |
Terminated |
NCT02179151 -
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
|
Phase 3 | |
Completed |
NCT02205450 -
Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
|
||
Completed |
NCT00375089 -
Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity
|
N/A | |
Completed |
NCT00004351 -
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
|
N/A | |
Recruiting |
NCT05938543 -
Cerebellar TMS and Satiety in Prader-Willi Syndrome
|
N/A | |
Suspended |
NCT05879614 -
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
|
Phase 2 | |
Recruiting |
NCT03031626 -
Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome
|
Phase 4 | |
Withdrawn |
NCT04086810 -
An Open-Label Study of DCCR Tablet in Patients With PWS
|
Phase 3 | |
Completed |
NCT02629991 -
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
|
Phase 2 | |
Recruiting |
NCT02297022 -
Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome
|
Phase 1 | |
Not yet recruiting |
NCT02263781 -
PREPL in Health and Disease
|
N/A | |
Completed |
NCT00551343 -
Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
|
N/A | |
Recruiting |
NCT06448871 -
Ultrasound to Assess Sarcopenia in Prader Willi Syndrome
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT05939453 -
Impact of Bright Light Therapy on Prader-Willi Syndrome
|
N/A |